arginine butyrate

protects against lethal effect of encelphalomyocarditis virus in mice; also used to administer butyrate to stimulate globin gene expression in beta-thalassemia and sickle cell anemia

Also Known As:

Networked: 31 relevant articles (2 outcomes, 6 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Perrine, Susan P: 6 articles (01/2012 - 06/2003)
2.	Faller, Douglas V: 5 articles (01/2012 - 04/2002)
3.	de la Porte, Sabine: 4 articles (11/2014 - 06/2010)
4.	Knight-Madden, Jennifer M: 3 articles (01/2021 - 11/2012)
5.	Martinez-Zapata, Maria José: 3 articles (01/2021 - 11/2012)
6.	Martí-Carvajal, Arturo J: 3 articles (01/2021 - 11/2012)
7.	Roulot, Morgane: 3 articles (11/2014 - 06/2013)
8.	Vianello, Sara: 3 articles (11/2014 - 06/2013)
9.	Benoit, Evelyne: 2 articles (11/2014 - 06/2014)
10.	Sebrié, Catherine: 2 articles (11/2014 - 06/2013)

Related Diseases

1.	Sickle Cell Anemia (Hemoglobin S Disease) 06/15/1995 - "Ten weeks of intravenous arginine butyrate did not produce a hematologic response in 10 patients with either severe beta-thalassemia or sickle cell disease." 11/01/2014 - "We studied in mdx mice, the effects of oral administration of arginine butyrate (AB), a compound currently used for the treatment of sickle cell anemia in children, on cardiomyopathy, vertebral column deformation and electromyographic abnormalities. " 06/15/1995 - "We treated 10 patients with severe beta-thalassemia or sickle cell disease with arginine butyrate at an initial dose of 500 mg per kilogram of body weight per day (final dose, 2000 mg per kilogram per day), 6 days per week, for a mean (+/- SD) of 10 +/- 1.2 weeks (range, 9 to 13). " 12/20/1996 - "Recent reports have demonstrated improvement in the clinical status and hemoglobin levels with use of intravenous arginine butyrate in patients with homozygous β-thalassemia and sickle cell disease. " 12/20/1996 - "To allow optimalization of therapy, we conducted pharmacokinetic studies in nine patients, five with sickle cell disease and four with β-thalassemia, treated with continuous intravenous infusion of arginine butyrate. "
2.	Thalassemia 07/01/1994 - "Intravenous arginine butyrate has been shown to increase fetal hemoglobin (HbF) in sickle cell and thalassemia patients. " 12/20/1996 - "Recent reports have demonstrated improvement in the clinical status and hemoglobin levels with use of intravenous arginine butyrate in patients with homozygous β-thalassemia and sickle cell disease. " 12/20/1996 - "To allow optimalization of therapy, we conducted pharmacokinetic studies in nine patients, five with sickle cell disease and four with β-thalassemia, treated with continuous intravenous infusion of arginine butyrate. " 10/01/1994 - "Rapid healing of chronic leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia." 06/15/1995 - "Intravenous infusion of arginine butyrate can increase the number of reticulocytes containing fetal hemoglobin in patients with these disorders, and it has induced a substantial increase in hemoglobin in one patient with thalassemia. "
3.	Fibrosis (Cirrhosis) 06/21/2010 - "Arginine butyrate treatment improved grip strength and decreased fibrosis in the gastrocnemius muscle, but did not produce significant improvement in muscle and cardiac histology, heart function, behavioral measurements, or serum creatine kinase levels. " 06/21/2010 - "These data indicate that 6 months treatment with arginine butyrate can produce modest beneficial effects on dystrophic pathology in mdx mice by reducing fibrosis and promoting muscle function while chronic continuous treatment with prednisone showed deleterious effects to skeletal and cardiac muscle. "
4.	Leg Ulcer 12/01/2010 - "These findings strongly suggest that Arginine Butyrate merits further evaluation for the treatment of refractory sickle cell leg ulcers in larger trials." 12/01/2010 - "Healing of leg ulcers was incidentally observed during dose-ranging trials of Arginine Butyrate in beta haemoglobinopathies. " 12/01/2010 - "A randomized phase II trial of Arginine Butyrate with standard local therapy in refractory sickle cell leg ulcers." 10/01/1994 - "Rapid healing of chronic leg ulcers during arginine butyrate therapy in patients with sickle cell disease and thalassemia." 01/01/2021 - "Three trials reported on complete leg ulcer closure (isoxsuprine, arginine butyrate, RGD peptide matrix; very low quality of evidence). "
5.	Neoplasms (Cancer) 09/01/2001 - "Arginine butyrate selectively activates the EBV TK gene in latently infected EBV-positive tumor cells. " 09/01/2001 - "Arginine butyrate selectively activates the EBV TK gene in latently EBV-infected human lymphoid cells and tumor cells. " 10/26/1981 - "Arginine butyrate slightly increases the resistance of Swiss Mice to allografted 180/TG tumor cells. " 10/26/1981 - "[Inhibitory effect of arginine butyrate on the development of Crocker 180/TG tumor in Swiss mice]." 03/15/2007 - "A phase 1/2 trial of arginine butyrate and ganciclovir in patients with Epstein-Barr virus-associated lymphoid malignancies."

Related Drugs and Biologics

1.	Hemoglobins (Hemoglobin)
2.	Creatine Kinase (Creatine Phosphokinase)
3.	Ganciclovir (Cytovene)
4.	arginyl-glycyl-aspartic acid
5.	Isoxsuprine
6.	Interleukin-2 (IL2)
7.	denileukin diftitox (Ontak)
8.	Butyrates (Butyrate)
9.	Histone Deacetylases (Histone Deacetylase)
10.	Fetal Hemoglobin (Hemoglobin F)

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Infusions
3.	Salvage Therapy
4.	Stents
5.	Oral Administration